Effect of Formica Rufa 30C on serum uric acid levels in Chronic Gout patients

Effectiveness Of Formica Rufa 30C In Patients Diagnosed With Chronic Gout Assessed by Serum Uric Acid Levels - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/02/103021

Enrollment

Registered

2026-02-04

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M1A9- Chronic gout, unspecified

Interventions

Intervention1: Formica Rufa 30C: The medicine will be prescribed based upon totality and 5 pills are administered OD for 21 days and repetition of the medication will be done for every 21 days based o

Eligibility

Inclusion criteria

Inclusion criteria: Patient diagnosed with Chronic gout with tophi and having acute flares of gout according to ICD11 classification FA25 with serum uric acid greater than 7 mg per dl

Exclusion criteria

Exclusion criteria: Patients with secondary hyperuricemia Causes- increased production -Leukemia, psoriasis, tumor lysis, obesity, hemolysis, polycythemia vera. Decreased excretion- CKD, diuretics, aspirin, lead, lactic acidosis Drugs-Thiazides, pyrazinamide, ethambutol, cyclosporine, tacrolimus Patients on allopathic drugs for gout (Urate lowering therapy) Renal failure, uncontrolled diabetes mellitus. Pregnant/lactating women. Patients diagnosed with other types of rheumatological conditions

Design outcomes

Primary

Measure	Time frame
Expected to have the changes in the serum uric acid levels in patients diagnosed with chronic gout after administering Formica rufa 30C within the time period of 6 monthsTimepoint: change in serum uric acid levels at Baseline 3rd month and 6th month	—

Secondary

Measure	Time frame
Expected to have the changes in Frequency of acute flares of pain episodes in patients diagnosed with chronic gout after administering Formica rufa 30C within the time period of 6 months, Expected to have the changes in frequency of NSAID usage during acute flare up of gout in patients diagnosed with chronic gout after administering Formica rufa 30C within the time period of 6 months.Timepoint: Frequency of acute flares of pain episodes in chronic gout and usage of NSAIDS during flares recorded in day dairy and cumilatively measured at Baseline 3rd month and 6th month	—

Measure

Time frame

Expected to have the changes in Frequency of acute flares of pain episodes in patients diagnosed with chronic gout after administering Formica rufa 30C within the time period of 6 months, Expected to have the changes in frequency of NSAID usage during acute flare up of gout in patients diagnosed with chronic gout after administering Formica rufa 30C within the time period of 6 months.Timepoint: Frequency of acute flares of pain episodes in chronic gout and usage of NSAIDS during flares recorded in day dairy and cumilatively measured at Baseline 3rd month and 6th month

—

Countries

India

Contacts

Public ContactDrKVarsha

JIMS Homoeopathic Medical College And Hospital

drbainusharma07@gmail.com6397159244

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026